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CLINICAL AND ECONOMIC CONSEQUENCES OF MEDICATION NON-
ADHERENCE IN THE TREATMENT OF PATIENTS WITH A MANIC/
MIXED EPISODE OF BIPOLAR DISORDER: RESULTS FROM THE 
EUROPEAN MANIA IN BIPOLAR LONGITUDINAL EVALUATION OF 
MEDICATION (EMBLEM) STUDY
Hong J1, Reed C2, Novick D2, Haro JM3, Aguado J3
1London School of Economics, London, UK, 2Eli Lilly and Company, Windlesham, Surrey, 
UK, 3Sant Joan de Deu-SSM, Barcelona, Spain
OBJECTIVES: To investigate the consequences of medication non-adherence on 
relapse, recurrence, remission and recovery, and to estimate costs associated with 
non-adherence over 21-months in the treatment of bipolar disorder following a manic 
or mixed episode. METHODS: EMBLEM is a prospective, observational study on 
patient outcomes with a manic/mixed episode. Data was collected at baseline, during 
the ﬁrst 12 weeks of treatment (acute phase), at 6 month post-baseline and at 6-month 
intervals up to 24 months (maintenance phase). Medication adherence was assessed 
at each visit by investigators as: i) not prescribed medication; ii) almost always adheres; 
iii) adheres half of the time; and iv) never adheres to medication. Adherence was 
deﬁned as always answering ‘always adheres’ and non-adherence was deﬁned when 
one or more response of ‘adheres half of the time’ or ‘never adheres’. In this post-hoc 
analysis, Cox proportional hazards models with non-adherence, adjusted for patient 
characteristics, investigated its impact on clinical outcomes. Multivariate analyses were 
performed to estimate the cost of resource use associated with non-adherence during 
the maintenance phase, using a log-link function. UK unit costs were applied to 
resource use. RESULTS: Of the 1341 patients analysed, 23.6% were non-adherent 
over 21-months. Non-adherence was signiﬁcantly associated with a higher risk of 
relapse (HR:2.40, 95%CI:2.04–2.83) and recurrence (HR:1.72, 95%CI:1.27–2.33) as 
well as lower remission rates (Hazard ratio (HR):0.71, 95%CI:0.59–0.86) and recov-
ery (HR:0.65, 95%CI:0.51–0.81). In addition, costs incurred by non-adherent patients 
during this period were signiﬁcantly higher than those of adherent patients (£10231 
vs. £7379). This disparity resulted mainly from differences in in-patient costs (£4796 
vs. £2150). CONCLUSIONS: Non-adherence in bipolar patients after a manic/mixed 
episode is associated with higher than twice the risk of relapse of adherent patients 
which has economic implications for health care providers. A study limitation is that 
adherence was assessed by investigators using a single-item measure.
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A COMPARISON OF TREATMENT PATTERNS AND COSTS FOR 
SUBJECTS NEWLY TREATED WITH DONEPEZIL VERSUS THOSE 
NEWLY TREATED WITH GALANTAMINE OR RIVASTIGMINE
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OBJECTIVES: To compare treatment patterns and health care costs among subjects         
newly treated with donepezil versus subjects newly treated with rivastigmine or galan-     
tamine. METHODS: This retrospective claims-based analysis utilized data from a 
large US managed care plan. Subjects were q50 years of age; ﬁlled q1 prescription 
for donepezil, rivastigmine, or galantamine from January 1, 2005–December 31, 2007; 
and were continuously enrolled for q18 months. Rivastigmine and galantamine 
cohorts were each matched to donepezil cohort at 1:3 ratio by propensity score. 
Logistic regression, Cox regression, and generalized linear models with gamma distri-
bution and log link were used to examine adherence (medication possession ratio 
q80%), persistence/discontinuation and total health care costs, as appropriate. 
RESULTS: Of 488 rivastigmine subjects, 33.0% were adherent and 69.3% discontin-
ued medication while the rates of adherence and discontinuation in the matched 1,464 
donepezil users were 42.4% and 60.7%, respectively. Compared with rivastigmine 
cohort, donepezil subjects were more likely to be adherent (OR: 1.395, 95% CI: 
1.117–1.742, p  0.003) and had a lower risk of discontinuation (RR: 0.827, 95% 
CI: 0.729–0.939, p  0.003). Mean annualized total health care costs did not 
differ signiﬁcantly between two cohorts (donepezil: $11,431; rivastigmine: $12,358), 
although donepezil appeared to be associated with lower costs in regression analysis 
(Cost Ratio: 0.898, 95% CI: 0.803–1.005, p  0.06). Of 597 galantamine subjects, 
36.5% were adherent and 65.7% discontinued medication while the rates of adher-
ence and discontinuation in the matched 1,791 donepezil users were 42.0% and 
60.6%, respectively. Donepezil users were more likely to be adherent than galantamine 
users (OR: 1.261, 95% CI: 1.038–1.534, p  0.020); however, discontinuation 
risk was similar. Annualized health care costs were similar in the two cohorts both 
bivariately (donepezil: $11,644; galantamine:$ 10,876) and in regression analysis. 
CONCLUSIONS: Donepezil users demonstrated better adherence than each of the 
matched cohorts, and lower discontinuation risk than the rivastigmine cohort. Total 
costs were similar.
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COMPARISON OF COST FOR DIFFERENT TESTS OF  
DEMENTIA SCREENING
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OBJECTIVES: Cost analysis of different dementia screening tests available in Spain 
from the health care system perspective. METHODS: A number of screening tests for 
General Practitioner (GP) consultation have been compared. According to their dura-
tion they were classiﬁed in long (5 minutes) and short (5 minutes) tests. The long 
tools evaluated were Mini-Mental State Examination (MMSE), a Spanish validated 
adaptation of MMSE (MEC-30), Eurotest and Memory Alteration Test (T@M). On 
the other hand, short tools evaluated were Fototest, Semantic Verbal Fluency (SVF), 
Memory Impairment Screen (MIS), Clock test (CT) and Short Portable Mental Status 
Questionnaire (SPMSQ) or Pfeiffer Test. Direct costs of the screening and the costs 
of veriﬁcation at hospital of the preliminary diagnosis were calculated. Costs by 
correct diagnosis (TP) have been calculated based on public prices of GP’s consulta-
tions and on analytical accounting of the public University Hospital Hospital Virgen 
de las Nieves (Granada, Spain). RESULTS: Total cost of each screening test was cal-
culated as the addition of the GP study for each patient (long screening a64.4a and 
short screening a43.5) plus the cost of the speciﬁc study for conﬁrmation at hospital 
for positive diagnosis (laboratory tests a123.61 and medical consultations a208.86 
per patient). Lower cost tests are Fototest (a527 per TP) and SPMSQ (a545.2 per TP). 
The rest of evaluated tests have higher costs (10–20%: CT, FVS, MEC-30 and 
Eurotest; 20–30%: MIS and T@M; 60%: MMSE). CONCLUSIONS: The MMSE, 
the most used screening test, is the most expensive. Fototest and SPMSQ are the 
screening test of lowest cost. Both tests are short, applicable to illiterates and show 
the same effectiveness as long tools. According to previous results, it may be recom-
mendable to take into account the differences among tests in terms of opportunity 
costs and potential budgetary impact, in the design of a broad regional screening 
dementia strategy.
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INITIAL PRESCRIPTION DOSE OF DULOXETINE AND 
HOSPITALIZATION AND HEALTH CARE COSTS FOR PATIENTS WITH 
MAJOR DEPRESSIVE DISORDER
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OBJECTIVES: Our recent study showed that multiple factors including patient 
characteristics, comorbidities, prior medications, prior health care utilization and 
costs were associated with initial prescription dosage of duloxetine in the treatment 
of major depressive disorder (MDD). The purpose of the present study was to 
examine the associations between initial prescription dosage of duloxetine and 
hospitalization and costs in the 1-year follow-up period. METHODS: Of 10,128 
patients with MDD in a large commercial administrative claims database who 
were initiated on duloxetine between July 1, 2005 and June 30, 2006 and had no 
prescriptions of duloxetine in the prior 6 months, 6132 (60.5%) had continuous 
enrollment for 12 months prior to and post-duloxetine initiation. According to 
initial prescription dose, patients were divided into 3 cohorts: low-dose (60 mg/day, 
n  1,989), mid-dose (60 mg/day, n  3,733), and high-dose (60 mg/day, n  410). 
Intent-to-treat analysis was conducted to compare health care utilization and costs in 
the 1 year prior and post-initiation across the 3 cohorts. RESULTS: During the post 
1 year, hospitalization rate was signiﬁcantly reduced by 5.7% for mid-dose cohort (p 
 0.001), 6.9% for high-dose cohort (p  0.05), and 7.3% for low-dose cohort (p  
0.001). Pharmacy costs in the post 1 year increased in all 3 cohorts: low-dose, $672 
(p  0.001); mid-dose, $825 (p  0.001); and high-dose, $1437 (p  0.05). However, 
mean medical costs declined in high-dose patients ($2617) and mid-dose patients 
($340), but increased in low-dose patients ($261). Mean total health care costs 
numerically declined by $1,180 ($20,225-$21,406) in high-dose patients, but increased 
in low-dose patients by $933 ($18,002–$17,069) and mid-dose patients by $485 
($16,917-$16,432), although these cost changes were not signiﬁcant. CONCLU-
SIONS: The hospitalization rate was signiﬁcantly reduced in all patients after dulox-
etine initiation. Although pharmacy costs increased more in high-dose patients than 
in mid- and low-dose patients; the higher medication costs were offset by lower 
medical costs.
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OBJECTIVES: This retrospective study aimed to compare health care utilization 
associated with duloxetine versus other antidepressants for patients with major depres-
sive disorder (MDD) in the Veterans Affairs (VA) health system. Duloxetine was not 
on the VA national drug formulary. METHODS: The electronic medical records 
from October 2004 to October 2008 were extracted from the VA Veterans Integrated 
Service Network 16 data warehouse. All patients were treated with either duloxetine 
monotherapy or other antidepressants (non-duloxetine) over the study period. 
The ﬁrst dispense date of the index agent was deﬁned as the index date. All patients 
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must have at least 1 prior MDD diagnosis (ICD-9-CM: 296.2 or 296.3), but no 
prior diabetes (ICD-9-CM: 250.xx) or bipolar disorder (ICD-9-CM: 296.4x–296.8x) 
diagnosis. The non-duloxetine patients were matched to the duloxetine patients 
via propensity scoring (1:1 ratio), controlling for differences in demographics, comor-
bidities, prior opioid use, and pain levels in the 12 months pre-index period. Paired 
t-tests were used to compare health care utilization over the 12 months post- 
index period including outpatient visits, emergency department (ED) visits, hospital 
admissions and length of hospital stay. Chi-square tests were used to compare 
percentages of patients with hospitalization or ED visit. RESULTS: The study 
sample included 878 patients (duloxetine: n  439; non-duloxetine: n  439) with 
comparable baseline characteristics. Compared with duloxetine patients, non-dulox-
etine patients on average had 12.0 more outpatient visits (95% Conﬁdence Interval 
[CI]: 6.4–17.5, p  0.0001), 0.16 more hospital admissions (CI: 0.07–0.26, p  0.001), 
and 0.79 more hospital days (CI: 0.17–1.41, p  0.013). Additionally, a higher per-
centage of non-duloxetine patients was hospitalized (17.8% vs. 10.9%, p  0.004). 
No group difference was found in ED visits. CONCLUSIONS: Controlling for cross-
cohort differences, VA patients who were treated with duloxetine were found to 
be associated with lower health care utilization than those treated with other 
antidepressants.
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A DYNAMIC MARKOV APPROACH ASSESSING THE BURDEN OF 
ILLNESS OF GENERALIZED ANXIETY (GAD) DISORDER IN CANADA
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OBJECTIVES: GAD is a chronic disease with waxing and waning of symptoms; 
exerting substantial economic and humanistic impact. To date, economic evaluations 
have been limited to time horizons of 12 months. This study develops a dynamic 
decision model, quantifying the lifetime cost-of-illness (COI) for GAD (direct and 
indirect costs). METHODS: TreeAge® software was used to develop an incidence-
based Markov model with 9 health-states (6-month cycles): Family physician assess-
ment (initial), Specialist assessment for 2nd and 3rd line therapies, Maintenance 
therapies, Treatment discontinued and Death (absorbing). Patients seeking treatment 
enter the model between the ages of 18–80 and subject to age of onset. Pharmaco-
therapy based on Canadian Psychiatric Association (CPA) guidelines; revised and 
validated by an expert panel. Meta-analysis of CPA-cited evidence populated remis-
sion and response rates. Published literature determined absenteeism, treatment 
 discontinuation, onset of illness, and relapse rates. Physician, pharmacotherapy, hos-
pitalization costs based on published public (Province of Ontario) rates. All cause 
mortality (2000–2002) and hourly wage rates (2008) published by Statistics Canada. 
COI was reported in 2008 Canadian dollars, discounted at 5%. A total of 10,000 
iterations were used for 1st order micro-simulation. RESULTS: Mean lifetime COI/
patient  $6671(SD  $4678). Mean age of onset  48 years. Mean (SD) tracker values: 
Relapse/patient  1(1.02); Treatment resistant patients  20%(40%); Discontinued 
treatment time  13(8) years. Absorbing state (Death) captures 89% of patients. The 
range of uncertainty for relapse (1–5%) and cost of absenteeism ($0-$6,071) exerted 
the highest impact of all variables on mean COI $5,000–8,000 and $1,000–$12,000 
respectively. Breakdown cost analysis: 82% absenteeism, 8% pharmacotherapy, 7% 
physician, 2% hospitalization. 85% of all patients discontinued treatment by 4th year). 
CONCLUSIONS: This is the ﬁrst known study to model the course of GAD over a 
patient’s lifetime and quantify COI. Absenteeism contributes substantially to the COI 
for GAD. Relatively low attribution of pharmacotherapy cost to COI possibly due to 
treatment discontinuation.
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MEASURING THE ECONOMIC BURDEN OF DEPRESSION USING 
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OBJECTIVES: To measure the total direct cost of depression and its distribution to 
different services using administrative databases from Alberta service providers. 
METHODS: We analyzed available administrative databases from Alberta Health and 
Wellness and the Alberta Mental Health Board from 2005–2006. The following cost 
information was obtained: psychiatric care, community mental health visits, regional 
inpatient and outpatient services, emergency room visits, and physician visits. Records 
were selected if the primary diagnosis for the service was depression disorder using 
2006 dollar values. Data was analyzed by age group. RESULTS: Depression in Alberta 
had a direct health care cost of $97 M in 2005–2006, representing 1.1% of the prov-
ince’s total health care costs. The treated prevalence of depression in 2005–2006 was 
estimated at 13%. The greatest cost driver was physician services ($42.6 M), followed 
by acute inpatient costs ($33.8 M). General practitioners incurred half of physician 
costs and treated nearly six times the number of individuals with depression than 
psychiatrists. Per capita cost to treat depression increases with age, with seniors rep-
resenting the highest cost per individual. Older adults tend to use and incur a greater 
cost in inpatient services, while outpatient or physician services are more heavily used 
by younger age groups. CONCLUSIONS: The estimated $97 M cost of depression in 
Alberta is likely to be an underestimation. We included individual data with a primary 
diagnosis of depression and could not include drug data or privately funded services. 
Our ﬁndings are consistent with previous research that people with depression are 
treated more frequently in primary care and that the cost to treat depression increases 
with age. Depression continues to be a heavy cost burden throughout Alberta and 
worldwide.
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OBJECTIVES: The main objective is to assess resource utilization and cost of schizo-
phrenia as well as cost drivers using a prospective cohort that followed a representative 
sample of 288 French patients. METHODS: This study is the ﬁrst comprehensive 
prospective study on cost of schizophrenia. Patients were randomly selected from three 
deﬁned catchment areas located in the North, Centre and South of France. Unit costs 
were based on the most valid available data, mainly health insurance and French 
public sources. Costs were deﬁned based on society perspective. Direct cost included 
treatment provided in inpatient services, intermediate facilities, outpatient visits and 
medication costs. Indirect costs were considered as productivity loss for unemployed 
or sick leave patients in working age. RESULTS: Average patient direct costs yield 
a3534, break down as 39.3% for inpatient treatment, 37.7% for day clinic, and 
16.1% for medication. The remaining includes visits to psychiatrists, GP’s, psycholo-
gists and other physicians. Assuming 1% prevalence of schizophrenia, the estimation 
of annual direct costs yields a1, 581, 111, 600, and indirect cost of schizophrenia 
linked to productivity loss in France yields a2, 214, 488, 006. Several cost drivers 
were identiﬁed: relapse during the follow-up period, positive symptoms of schizophre-
nia, and depressive symptoms at baseline predict higher costs, while satisfaction with 
their health or negative symptoms of schizophrenia at baseline was linked with lower 
costs. CONCLUSIONS: This study highlights the heavy societal burden of schizophre-
nia in France, of which hospitalization (day and full time) services account for 77%. 
Any attempt to anticipate and prevent hospitalization might have signiﬁcant effect on 
the cost of schizophrenia. Such intervention is likely to be cost effective.
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REALLY MEASURING?
Gil E1, Medina E1, Cordero L2, Valero G1, Rovirosa A1
1AstraZeneca Farmacéutica Spain S.A., Madrid, Spain, 2AstraZeneca Farmacéutica Spain S.A, 
Madrid, Spain
OBJECTIVES: Bipolar disorder (BD) is a long-term condition that has a high impact 
on patients, families, health care systems and society. One of the main challenges in 
mental health is to determine the burden associated with it. The purpose is to establish 
the different perspectives and measures used to asses the burden of BD. METHODS: 
A systematic review was performed to identify studies in PUBMED, MEDLINE, 
EMBASE and Cochrane library. The search strategy used the MeSH terms: “bipolar 
disorder” & “cost of illness”, combined with “burden of disease”, “disease burden” 
& “burden of illness”. There weren’t constrains on date or language. Titles and 
abstracts were examined by reviewers, selecting for inclusion articles reporting an 
explicit aim to evaluate the burden of BD, measured by prevalence, morbidities associ-
ated, lost of quality of life, disabilities, impairments and/or costs. Articles were classi-
ﬁed into 4 categories, depending on focus studied: 1) patients; 2) caregivers (family, 
partners); 3) health care-system; and 4) society. RESULTS: A total of 188 articles were 
identiﬁed, 32 met study criteria. Eleven studies were reviews, and 21 were manuscripts, 
classiﬁed as 53.1% caregivers (n  17), 28.2% health care-system (n  10), 15.6% 
patients (n  5) and 3.1% society (n  1). The main outcome measures were: distress 
and subjective burden in caregivers scope, costs in health care-system, morbidity in 
patients and a set of all (prevalence, patient-related issued, disabilities and costs) in 
society. CONCLUSIONS: Concept of burden of disease varies depending on the 
studies perspectives and researchers concern. Our study suggests that the main interest 
when evaluating the burden of BD is focused on assessing the impact of the disease 
on relatives. As BD causes a high level of impairments and disabilities, that affects 
specially to caregivers, costs associated with it are difﬁcult to estimate. Additional 
research is needed in order to determine them properly.
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OBJECTIVES: Data concerning costs of illness in patients with schizophrenia are          
scarce in Germany. Aim of this claims data analysis was to examine the costs of 
schizophrenia from the perspective of a major statutory health insurance fund. 
METHODS: A nation-wide database was used to evaluate the costs of schizophrenia           
in 2006. All patients with schizophrenia (ICD F20) were identiﬁed via a special algo-
rithm based on claims data. All schizophrenia related costs for outpatient care, inpa-
tient care, medications, rehabilitation, occupational therapy, and sick leave payments 
were analysed. RESULTS: Data from 11,513 patients were available, with 47%        
being female (and 46 years of age). Mean costs of EUR 4,966 in the year 2006 were 
incurred from the health insurance perspective. A total of a2924 (59 %) were incurred 
by inpatient care, and a1333 (27 %) were due to medication. A total of a421 (8 %) 
resulted from schizophrenia related outpatient psychological specialists visits. Costs 
